+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treatment by continuous infusion with Monoclonal Antibody Purified factor IX in hemophilia B patients in surgical, trauma, or severe spontaneous hemorrhage



Treatment by continuous infusion with Monoclonal Antibody Purified factor IX in hemophilia B patients in surgical, trauma, or severe spontaneous hemorrhage



Blood 98(11 Part 1): 532a, November 16



Continuous infusion (CI) may be the preferable modality for treatment due to a more precise maintenance of desired plasma factor IX levels and the resulting diminished cost of treatment secondary to an overall decrease in factor IX requirements. Mononine(R), Coagulation Factor IX (Human), Monoclonal Antibody Purified, is approved for factor IX replacement therapy in hemophilia B patients by intravenous (IV) bolus. The clinical safety and efficacy of Mononine(R) replacement therapy administered by CI in mild, moderate, and severe hemophilia B patients during surgery or after trauma or severe spontaneous hemorrhage has been evaluated in an international, multicenter, open-label study. In this trial, factor IX recovery and half-life are determined prior to planned elective surgery (but are not required for actively bleeding patients). Patients first receive an IV bolus injection of product to reach a target factor IX:C level of gtoreq0.4 to 1.0 IU/mL. CI therapy is then initiated to maintain preoperative and postoperative factor IX:C at the same level for up to 6 days. The CI dosage is calculated using the clearance determined for the individual patient. Efficacy of therapy is determined by the investigators in comparison to patients without hemostatic disorders undergoing similar procedures and rated on a five-point scale ("excellent"=normal hemostasis, "good"=slight oozing at surgical site, "fair"=mild bleeding, "poor"=moderate bleeding, "none"=severe bleeding). Twenty-eight patients (25 surgery, 2 trauma, 1 severe spontaneous hemorrhage) were enrolled in to the study. A median intravenous bolus dose of 54.2 IU/kg FIX was administered to a subset of 13 non-emergency patients 7-21 days prior to CIV infusion to determine pharmacokinetic parameters. The overall mean half-life was 16.7 hours (range, 8.7-36.6); mean clearance was 4.5 mL/h/kg (range, 2.5-9.7); and the mean in vivo recovery (IVR) was 1.20 (IU/dL)/(IU/kg) (range, 0.65-1.6). During the bleeding/surgery episode, the median dose of FIX administered by bolus injection was 89.6 IU/kg (range, 12.4-108.3). Following the bolus injection, a median total CIV infusion dose of 396.4 IU/kg (range, 44.9-785.5) was administered at a median rate of 3.84 IU/kg/hour (range, 1.74-7.33) for 107.17 hours (range, 31.75-144). Overall hemostatic efficacy was rated as "excellent" (normal hemostasis) for 23 of 24 (96%) patients and as "good" (slight oozing) for one patient (bilateral knee replacement). Median FIX:C was 72%-86% for all patients receiving FIX by CIV on all days. No patient has experienced thrombotic complications, anaphylaxis, or inhibitor development. Continuous infusion of Mononine(R) resulted in safe and effective hemostatic coverage of surgical procedures and bleeding episodes among patients with mild to severe hemophilia B.

(PDF emailed within 1 workday: $29.90)

Accession: 035980085

Download citation: RISBibTeXText


Related references

Half-life, recovery and efficacy of continuous infusion monoclonal antibody purified factor IX in hemophilia B surgical, trauma, or severe spontaneous hemorrhage patients. Blood 90(10 SUPPL 1 PART 1): 35A, Nov 15, 1997

Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Management by continuous infusion of monoclonal antibody-purified factor VIII. American Journal of Pediatric Hematology/Oncology 15(1): 107-110, 1993

Safety and efficacy of monoclonal antibody purified factor IX concentrate for management of spontaneous or trauma-induced bleeding and surgical prophylaxis in children with hemophilia B. Pediatric Research 35(4 PART 2): 163A, 1994

Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious hemorrhage in patients with allo/autoantibodies to factor VIII. American Journal of Hematology 45(2): 142-145, 1994

Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thrombosis & Haemostasis 73(5): 779-784, 1995

Compassionate treatment with a monoclonal antibody-purified factor IX concentrate in hemophilia B surgical patients who have experienced thrombotic complications with prothrombin complex concentrates. Blood 82(10 SUPPL 1): 154A, 1993

Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. Thrombosis and Haemostasis 73(5): 779-784, 1995

Successful treatment with continuous infusion of coagulation factor concentrates in severe hemophilia A complicated with mixed trauma, crush syndrome and acute renal failure. Medicina 41(10): 857-860, 2005

Lack of immune response to mouse IgG in previously untreated hemophilia A and hemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations. Blood 86(10 SUPPL 1): 868A, 1995

Continuous infusion of monoclonal antibody-purified factor VIII. American Journal of Hematology 36(3): 211-212, 1991

Immune tolerance induction by continuous infusion of monoclonal antibody-purified factor VIII in children. Blood 82(10 SUPPL 1): 62A, 1993

Stability and sterility of dilute solutions of monoclonal antibody purified factor IX concentrate prepared for continuous infusion. Blood 86(10 SUPPL 1): 886A, 1995

The efficacy of continuous infusion of monoclonal factor viii products in patients with hemophilia. Transfusion (Bethesda) 30(3): 278, 1990

Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thrombosis and Haemostasis 75(1): 30-35, 1996